<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sinclair, Heather Q.</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Windecker, Stephan</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">The Impact of EES versus SES on Long-Term Clinical Outcome: Results from the LESSON-I Study</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">12-12</style></pages><abstract><style  face="normal" font="default" size="100%">Long-term follow-up (up to 3 years) that compared everolimus-eluting (EES) and sirolimus-eluting stents for coronary revascularization revealed that the unrestricted use of EES was associated with lower risk of myocardial infarction, target vessel revascularization, and stent thrombosis. The Long-term comparison of Everolimus-eluting and Sirolimus-eluting Stents for cOronary revascularizatioN [LESSON-I] data are discussed in this article.</style></abstract><number><style face="normal" font="default" size="100%">8</style></number><volume><style face="normal" font="default" size="100%">10</style></volume></record></records></xml>